[177Lu]Lu-PSMA-617 (177Lu-PSMA-617) is a high-affinity PSMA-targeted small-molecule radioligand therapy that delivers β-particle radiation specifically to prostate cancer lesions (8–10). Here, FOLH1 is linked to prostate carcinoma.